Biobetters : Protein Engineering to Approach the Curative /
| Autor Corporativo: | |
|---|---|
| Otros Autores: | , |
| Formato: | eBook |
| Lenguaje: | English |
| Publicado: |
New York, NY :
Springer New York : Imprint: Springer,
2015.
|
| Edición: | 1st ed. 2015. |
| Colección: | AAPS Advances in the Pharmaceutical Sciences Series,
19 |
| Materias: |
Tabla de Contenidos:
- Introduction
- Targeting glucocerebrosidase to macrophages for effective treatment of patients with Gaucher disease: setting the paradigm of a "fit for purpose" approach to enzyme replacement therapy
- Challenges of Enzyme Replacement Therapy: Poor tissue distribution in lysosomal diseases using Pompe disease as a model
- Muscle targeting
- Blood-Brain Barrier Targeting of Therapeutic Lysosomal Enzymes
- Novel Methods for Addressing Immunogenicity in Therapeutic Enzymes
- Structure of monoclonal antibodies
- Prediction of aggregation in vivo by studies of therapeutic proteins in human plasma
- Effect of Hydrolytic Degradation on the In Vivo Properties of Monoclonal Antibodies
- Oxidation of proteins in the in-vivo environment: what we know; what we need to study and potential mitigation strategies
- Molecular assessment: balancing affinity, PK and manufacturability
- Perspectives on engineering biobetter therapeutic proteins with greater stability in inflammatory environments
- Antibody-like molecules designed for superior targeting and pharmacokinetics
- Alternative protein scaffolds as novel biotherapeutics
- Current strategies for pharmacokinetic optimization
- Biosimilar and Biobetter Scenarios for the US and Europe: What Should We Expect?
- Regulatory considerations for approval of biobetter products.